Almost one-half of patients referred to a phase 1 clinical trial predicted tumor shrinkage as a result of participating in the phase I clinical trial.  These rates conflict with the typical phase I response rates of 4% to 20%, and this discrepancy demonstrates the challenges facing patients and healthcare professionals during their interactions in phase I studies. (cancer network.com)